Evox Therapeutics, an exosome therapeutics company, has published Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes in Nature Communications. This follows a research collaboration and option agreement with the Icahn School of… Read More
Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving… Read More
Evox Therapeutics has purchased Codiak Biosciences engEx-AAV technology platform, including all intellectual property rights, and exclusive access to certain engineering and manufacturing rights. The technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient… Read More
